Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor
Abstract Background Primaquine, an 8-aminoquinoline with anti-hypnozoite activity against Plasmodium vivax, is metabolized by human cytochrome P450 2D6 (CYP2D6) to its active metabolite. Human CYP2D6 activities may influence the metabolism of primaquine and the risk of experiencing Plasmodium relaps...
Main Authors: | Nanhua Chen, Simone Dowd, Michelle L. Gatton, Alyson Auliff, Michael D. Edstein, Qin Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Malaria Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12936-019-2774-2 |
Similar Items
-
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function
by: Alexandra Martin Ramírez, et al.
Published: (2020-07-01) -
Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases
by: Anielle de Pina-Costa, et al.
Published: (2021-08-01) -
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
by: J. Kevin Baird, et al.
Published: (2018-01-01) -
Population Pharmacokinetics of Primaquine in the Korean Population
by: Woo-Yul Lee, et al.
Published: (2021-05-01) -
The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China
by: Herong Huang, et al.
Published: (2021-03-01)